Statement about Media Articles as to Takeda's Acquisition of a Swiss Company

Osaka, Japan, May 13, 2011 --- Takeda Pharmaceutical Company Limited ("Takeda") has and always will comply with the rules governing the publication of any event of material significance to our business and our shareholders. The company would like to make clear that Takeda has not agreed to any such an agreement as suggested by certain newspaper publications. In addition, Takeda has a policy of not commenting on any rumors regarding our business.

Takeda is constantly seeking and evaluating opportunities to increase shareholder value and enhance our business through strategic investment, however, there is nothing that needs to be announced at this point.

Suggested Articles

WuXi names Dong to helm new vaccines CDMO; Paragon appoints Jimenez as capital makers lead; Levy joins Spark as CMO.

The phase 1 and 2 results suggest the vaccine may be safe, tolerable and capable of triggering production of antibodies against the coronavirus.

The platform, which is in use at companies including Agios, enables researchers to simultaneously detect DNA and protein changes in single cells.